Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001558370-23-006263
Filing Date
2023-04-20
Accepted
2023-04-20 07:01:31
Documents
19

Document Format Files

Seq Description Document Type Size
1 DEF 14A acrs-20230601xdef14a.htm   iXBRL DEF 14A 1377270
2 GRAPHIC acrs-20230601xdef14a_a001.jpg GRAPHIC 4507
3 GRAPHIC acrs-20230601xdef14a_a015.jpg GRAPHIC 60308
4 GRAPHIC acrs-20230601xdef14a_a016.jpg GRAPHIC 55523
5 GRAPHIC acrs-20230601xdef14a_bg001.jpg GRAPHIC 144031
6 GRAPHIC acrs-20230601xdef14a_bg002.jpg GRAPHIC 102395
  Complete submission text file 0001558370-23-006263.txt   3052639

Data Files

Seq Description Document Type Size
7 EX-101.SCH acrs-20230601.xsd EX-101.SCH 5375
8 EX-101.DEF acrs-20230601_def.xml EX-101.DEF 6542
9 EX-101.LAB acrs-20230601_lab.xml EX-101.LAB 12680
10 EX-101.PRE acrs-20230601_pre.xml EX-101.PRE 6481
13 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20230601xdef14a_htm.xml XML 237962
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37581 | Film No.: 23831376
SIC: 2834 Pharmaceutical Preparations